Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort)

The non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz (EFV) and nevirapine (NVP) taken in combination with nucleoside reverse transcriptase inhibitors (NRTIs) have both shown to be just as highly effective as protease inhibitors (PIs) in reducing viral load in patients infected with...

Full description

Saved in:
Bibliographic Details
Published in:International journal of STD & AIDS 2005-06, Vol.16 (6), p.404-409
Main Authors: HARTMANN, Martin, WITTE, Steffen, BRUST, Jurgen, SCHUSTER, Dieter, MOSTHAF, Franz, PROCACCIANTI, Maria, RUMP, Joerg Andres, KLINKER, Hartwig, PETZOLDT, Detlef
Format: Article
Language:English
Subjects:
AIDS/HIV
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Benzoxazines
Biological and medical sciences
Drug Therapy, Combination
Epidemiology. Vaccinations
Female
General aspects
HIV Infections - drug therapy
HIV Infections - physiopathology
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - physiology
Human viral diseases
Humans
Infectious diseases
Male
Medical sciences
Nevirapine - administration & dosage
Nevirapine - therapeutic use
Oxazines - administration & dosage
Oxazines - therapeutic use
Pharmacology. Drug treatments
Prospective Studies
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Load
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz (EFV) and nevirapine (NVP) taken in combination with nucleoside reverse transcriptase inhibitors (NRTIs) have both shown to be just as highly effective as protease inhibitors (PIs) in reducing viral load in patients infected with HIV. Our study compares the performance of these two NNRTIs with each other. This was a non-randomized, prospective, two-arm, multi-centre trial. We evaluated all patients with an EFV- or NVP-containing antiretroviral regimen. The primary endpoint was the difference in success rates defined as a viral load of
ISSN:0956-4624
1758-1052
0956-4624
DOI:10.1258/0956462054094060